Kymera Investor Day Presentation Deck
In the OCI-LY10 MYD88MT
xenograft model, intermittent
dosing of KT-413 induced strong
antitumor activity, including
complete or partial regressions.
●
KT-413 is Highly Active on Intermittent Dosing Regimens
Superior Anti-tumor activity
OCI-Ly-10 Tumor Volume
Superior activity compared to the
clinically active IRAK4-inhibitor
CA-4948 or the IMID CC-220 alone
Single 10 mg/kg dose showed
extended tumor exposure and
strong degradation of both IRAK4
and IMID substrates that was
maintained for least 72hr
KYMERA
Single 10 mg/kg dose Q3W had
robust anti-tumor activity
©2021 KYMERA THERAPEUTICS, INC.
Tumor Volume (mm³)
Mean, ± SEM
2500
2000
1500
1000
500
0
0
7
14
21
28
Days After the Start of Treatment
10000
1000-
100-
10-
1-
Plasma
48
35
IV Vehicle
CA-4948, 150 mg/kg, PO, QD x 37
CC-220, 3 mg/kg, PO, QD x 21
KT-413,5 mg/kg, IV, D1,2,15,16
→ KT-413, 10 mg/kg, IV, D1,2,21,22
KYMERA R&D DAY - December 16th, 2021
Tumor
Drug (day 33)
CA-4948
CC-220
KT-413 5mg/kg
KT-413 10 mg/kg
IRAK4
96
144
Time (hr) Post Single-dose
Ikaros
192
240
T/C%
(REG%)
9
9
(14)
(94)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
CR
0
0
1
5
PR SD
0
O
0
2
O
0
3
0
PD
7
7
3
0
PAGE 53View entire presentation